Aug 7 (Reuters) - A New York-based hedge fund which owns 17 percent of Acorda Therapeutics Inc called on the U.S. developer of drugs targeting neurological disorders on Monday to explore a sale of the company, according to a regulatory filing with the U.S. Securities and Exchange Commission.